GTCbio, San Diego, CA
July 23-24, 2007
As the pharmaceutical and diagnostic industries develop more and more biomarkers, their importance and influence in all aspects of drug discovery and development process have reached new heights. With the biomarker industry projected to become a $21.2 billion industry by 2012, an increased number of pharmaceutical companies have entered the market. Between the augmented biomarker discoveries and ongoing validations by the FDA, a periodic refresher is required to stay ahead of the curve. GTCBio’s Rediscovering Biomarker conference covers a wide range of topics including: Adaptive Designs using Biomarkers
Proteomics Approaches for Discovery of Novel Cancer Biomarkers & Validation
Gaining Senior Level Buy-in for Successful Biomarker Deployment
Latest technological and biomarker trends Who should attend: You will benefit from attending this conference if you are a principal scientist, executive or senior-level director from the pharmaceutical and diagnostic industries with responsibilities or involvement in the following areas: Biomarker Development
Research and Development
Clinical Research
Drug Discovery
Molecular Sciences and Molecular Medicine
Pharmaometrics and Pharmacokinetics
Proteomics, Genomics, and Bioinformatics
Discovery Medicine and Discovery Oncology
Biological Sciences
Preclinical Development
Business Development
Marketing This conference will also benefit consultants and providers working in the area of biomarker development, discovery, and validation.
|
|